首页|Challenges of NK cell-based immunotherapy in the new era

Challenges of NK cell-based immunotherapy in the new era

扫码查看
原文链接
  • NETL
  • NSTL
  • 维普
  • 万方数据
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization.Various cellular sources,including peripheral blood mononuclear cells (PBMCs),stem cells,and NK cell lines,have been used for producing NK cells.In particular,NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not.However,considering the safety,activities,and reliability of the cell products,researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen.In this review,the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.

natural killer cellsimmunotherapyadoptive transfergenetic modificationimmune checkpoint inhibitor

Fang Fang、Weihua Xiao、Zhigang Tian

展开 >

Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei 230027, China

Hefei National Laboratory for Physical Sciences at Microscale, Hefei 230027, China

This work was supported by the National Natural Science Foundation of ChinaThis work was supported by the National Natural Science Foundation of ChinaThis work was supported by the National Natural Science Foundation of ChinaThis work was supported by the National Natural Science Foundation of ChinaThis work was supported by the National Natural Science Foundation of ChinaMinistry of Science and Technology of Chinaand Chinese Academy of Sciencesand Chinese Academy of Sciencesand Chinese Academy of Sciencesand Chinese Academy of Sciences

817881019154200081671558315714402016YFC1303503XDA12020312XDPB030301XDPB030303

2018

医学前沿
高等教育出版社

医学前沿

CSCDSCI
影响因子：1.362
ISSN：2095-0217
年,卷(期)：2018.12(4)
  • 5
  • 7